Assessing Amyloid Pathology in Cognitively Normal Subjects Using 18 F-Flutemetamol PET: Comparing Visual Reads and Quantitative Methods

Lyduine E. Collij, Elles Konijnenberg, Juhan Reimand, Mara Ten Kate, Anouk den Braber, Isadora Lopes Alves, Marissa Zwan, Maqsood Yaqub, Daniëlle M.E. van Assema, Alle Meije Wink, Adriaan A. Lammertsma, Philip Scheltens, Pieter Jelle Visser, Frederik Barkhof, Bart N.M. van Berckel

Research output: Contribution to JournalArticleAcademicpeer-review

Abstract

Our objective was to determine the optimal approach for assessing amyloid disease in a cognitively normal elderly population. Methods: Dynamic 18F-flutemetamol PET scans were acquired using a coffee-break protocol (a 0- to 30-min scan and a 90- to 110-min scan) on 190 cognitively normal elderly individuals (mean age, 70.4 y; 60% female). Parametric images were generated from SUV ratio (SUVr) and nondisplaceable binding potential (BPND) methods, with cerebellar gray matter as a reference region, and were visually assessed by 3 trained readers. Interreader agreement was calculated using κ-statistics, and semiquantitative values were obtained. Global cutoffs were calculated for both SUVr and BPND using a receiver-operating-characteristic analysis and the Youden index. Visual assessment was related to semiquantitative classifications. Results: Interreader agreement in visual assessment was moderate for SUVr (κ = 0.57) and good for BPND images (κ = 0.77). There was discordance between readers for 35 cases (18%) using SUVr and for 15 cases (8%) using BPND, with 9 overlapping cases. For the total cohort, the mean (±SD) SUVr and BPND were 1.33 (±0.21) and 0.16 (±0.12), respectively. Most of the 35 cases (91%) for which SUVr image assessment was discordant between readers were classified as negative based on semiquantitative measurements. Conclusion: The use of parametric BPND images for visual assessment of 18F-flutemetamol in a population with low amyloid burden improves interreader agreement. Implementing semiquantification in addition to visual assessment of SUVr images can reduce false-positive classification in this population.

Original languageEnglish
Pages (from-to)541-547
Number of pages7
JournalJournal of nuclear medicine : official publication, Society of Nuclear Medicine
Volume60
Issue number5
Early online date12 Oct 2018
DOIs
Publication statusPublished - May 2019

Funding

This project received funding from the EU/EFPIA Innovative Medicines Initiative (IMI) Joint Undertaking (EMIF grant 115372) and the EU-EFPIA IMI-2 Joint Undertaking (grant 115952). This joint undertaking receives support from the European Union’s Horizon 2020 research and innovation program and EFPIA. Support was also received from the NIHR UCLH Biomedical Research Center, and in-kind sponsoring of the PET tracer was received from GE Healthcare. Philip Scheltens received grants from GE Healthcare, Piramal, and Merck, paid to his institution, and speaker’s fees paid to the Alzheimer Center, VU University Medical Center, Lilly, GE Healthcare, and Roche. Pieter Jelle Visser received research support from Biogen and grants from EU/EFPIA IMI Joint Undertaking, EU Joint Programme–Neurodegenerative Disease Research (JPND), ZonMw, and Bristol-Myers Squibb; served as a member of the advisory board of Roche Diagnostics; and received nonfinancial support from GE Healthcare. Frederik Barkhof received payment and honoraria from Bayer-Schering Pharma, Sanofi-Aventis, Gen-zyme, Biogen-Idec, TEVA, Merck-Serono, Novartis, Roche, Jansen Research, IXICO Ltd., GeNeuro, and Apitope Ltd. for consulting; payment from the Serono Symposia Foundation, IXICO Ltd., and MedScape for educational presentations; and research support via grants from EU/EFPIA Innovative Medicines Initiative Joint Undertaking (AMYPAD consortium), EuroPOND (H2020), U.K. MS Society, Dutch MS Society, PICTURE (IMDI-NWO), and ECTRIMS-MAGNIMS. No other potential conflict of interest relevant to this article was reported.

FundersFunder number
Bayer-Schering Pharma
Biogen-Idec
Dutch MS Society
ECTRIMS-MAGNIMS
EU-EFPIA IMI-2
EU/EFPIA
EU/EFPIA Innovative Medicines Initiative
EuroPOND
IMDI-NWO
Merck-Serono
Piramal
Serono Symposia Foundation
Bristol-Myers Squibb
Novartis
Roche
Sanofi
Biogen
Teva Pharmaceutical Industries
GE Healthcare
Horizon 2020 Framework Programme
Seventh Framework Programme115372, 115952
EU Joint Programme – Neurodegenerative Disease Research
European Federation of Pharmaceutical Industries and Associations
Multiple Sclerosis Society
ZonMw
Horizon 2020
Innovative Medicines Initiative
IXICO

    Keywords

    • 18F-flutemetamol PET
    • amyloid pathology
    • preclinical Alzheimer disease
    • visual assessment

    Fingerprint

    Dive into the research topics of 'Assessing Amyloid Pathology in Cognitively Normal Subjects Using 18 F-Flutemetamol PET: Comparing Visual Reads and Quantitative Methods'. Together they form a unique fingerprint.

    Cite this